title: 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
authors.forename: Ching-Chan
authors.initials: CC
authors.lastname: Lin
authors.forename: Te-Chun
authors.initials: TC
authors.lastname: Hsia
authors.forename: Chun-Ru
authors.initials: CR
authors.lastname: Chien
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000191:economics*; D011799:Quinazolines / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride